Corporate Banner
Satellite Banner
Metabolomics & Lipidomics
Scientific Community
Become a Member | Sign in
Home>News>This Article

Metabolon’s Quantose™ IR Test Featured in Five Poster Presentations at 2012 ADA Meeting

Published: Tuesday, June 12, 2012
Last Updated: Tuesday, June 12, 2012
Bookmark and Share
Clinical data demonstrate test’s effectiveness in stratifying prediabetic patients based on insulin resistance levels.

Metabolon, Inc. has announced that the clinical utility of the Company’s lead diagnostic product Quantose™ IR will be featured in five poster presentations at the 72nd Annual Scientific Sessions of the American Diabetes Association (ADA) being held June 8-12 in Philadelphia.

Quantose IR is a fasting blood test to measure insulin resistance (IR). The test measures levels of three novel non-glycemic biomarkers and insulin to detect prediabetes earlier and with greater sensitivity than traditional glycemic markers such as glucose and Hemoglobin A1C.

“This marks our fourth consecutive ADA annual meeting and our expanded presence this year reflects our Company’s continued focus on developing diagnostic tests related to metabolic disease,” said John Ryals, President and CEO of Metabolon.

Ryals continued, “As insulin resistance is known to precede Type 2 diabetes by up to 10 years, Quantose IR offers clinicians a tool for identifying patients at greatest risk for disease progression long before glycemic markers show evidence of dysregulation. Clinicians seeking to intervene in this high-risk group will be provided unique pathophysiological insight helpful in tailoring treatments to individual patients. Our Quantose IR test also provides a useful therapeutic monitoring tool to complement traditional markers in gauging treatment effectiveness due to its non-glycemic markers tracking so closely with changing insulin sensitivity.”

The following five abstracts related to Metabolon’s ongoing research and development efforts associated with Quantose IR will be featured at the ADA meeting:

“Early metabolic markers of the development of dysglycemia and Type 2 diabetes and their physiological significance”
• Alpha-hydroxybutyrate (AHB) and linoleoyl-glycerophosphocholine (L-GPC) are described as novel circulatory markers of insulin resistance, with clinical outcome data demonstrating their predictive risk to prediabetes and Type 2 diabetes and response to intervention.

Additional studies are presented that examine the Quantose IR biomarker’s physiological significance such as their bioactivity on insulin secretion. Abstract # 1600-P, to be presented by Dr. Walter Gall during the Monday, June 11th 12-2pm poster session.

“Pioglitazone improves insulin sensitivity by modulating novel biomarkers in impaired glucose tolerance” (Audio poster tour)
• Top-ranking insulin sensitivity biomarkers are measured in the T2D prevention study ACT NOW. The purpose of the study was to describe the response of the novel Quantose IR metabolites and its algorithm IR signature to pioglitazone pharmacotherapy and provide context of these observations in a diabetes prevention clinical setting.

Abstract # 1182-P, to be presented by Dr. Walter Gall during the Saturday, June 9th 11:30am-1:30pm poster session and the Sunday, June 10th 12-1pm guided audio tour.
“Metabolomic profile associated with hepatic insulin resistance in nondiabetic subjects: results from RISC study” (Audio poster tour)
• Quantose IR metabolites AHB and L-GPC are associated with hepatic insulin resistance, non-alcoholic fatty liver disease and NASH, further validating the clinical importance of measuring these novel biomarkers associated with IR-related disease outcomes. Abstract # 1791-P, to be presented by Dr. Amalia Gastadelli during the Monday, June 11th 12-2pm poster session.

“Effect of aging and exercise on novel insulin sensitivity marker linoleoyl-glycerophosphocholine” (Audio poster tour)
• Lifestyle intervention study with sedentary IR subjects demonstrate the response of Quantose IR metabolites AHB and L-GPC to aerobic exercise and further show associations of L-GPC with aging.

Abstract # 714-P, to be presented by Dr. Jose de Jesus Garduno Garcia during the Monday, June 11th 12-2pm poster session and the Monday, June 11th 1-2pm guided audio tour.

“Genetic variants associated with diabetes related circulating metabolite levels and their role in type 2 diabetes and insulin sensitivity”
• Genome-wide association studies were carried out with the RISC and Botnia prospective studies to identify and validate associations of genes and metabolites related to glycine, the top-ranking amino acid related to insulin sensitivity and proximal to Quantose IR metabolite AHB biosynthesis. Abstract # 1526-P, to be presented by Dr. Weijia Xie during the Monday, June 11th 12-2pm poster session.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Metabolon Launches Strategic Outsourcing Programs Focused On Disease Metabolism
Metabolon’s partners will collaborate toward shared objectives through this program.
Monday, October 15, 2012
Metabolon Files Patent Infringement Lawsuit against Stemina
The lawsuit requests monetary damages as well as an order permanently enjoining Stemina from continued acts of infringement.
Tuesday, August 28, 2012
Metabolon Strengthens Metabolomics Leadership with Acquisition of Lipomics Technologies
Gains proprietary lipids technology platform and further opportunities for diagnostics, personalized medicine and commercial services.
Friday, August 03, 2012
Metabolon Technology Now Available in Germany
The Helmholtz Zentrum Muenchen, Research Center for Environmental Health in Neuherberg, Germany, has successfully completed Metabolon’s validation requirements.
Friday, July 13, 2012
Metabolon’s Shanghai Jiao Tong University Lab Receives Validation
The joint metabolomics laboratory passed the quality control processes and has officially started operation.
Monday, May 14, 2012
Takeda and Metabolon Initiate Research Collaboration
Multiyear research alliance to discover novel targets and biomarkers.
Wednesday, April 18, 2012
Metabolon Awarded Analytical Methods Patent
The patented method enables the researcher to process, analyze and interpret data more efficiently.
Thursday, March 29, 2012
Metabolon Receives Accreditation by College of American Pathologists
Metabolon, Inc. announces that they have received laboratory accreditation from the College of American Pathologists (CAP).
Tuesday, December 06, 2011
Metabolomics Insight into Periodontal Disease Published in the Journal of Dental Research
Data reveal altered host-bacteria interactions associated with periodontitis.
Monday, October 24, 2011
Metabolon and SJTU Open Metabolomics Lab in China
Shanghai facility is company’s first foray into Asia.
Tuesday, October 18, 2011
Genome Wide Association Study Published in Nature
Metabolon, Inc. announces the publication of “Human Metabolic Individuality in Biomedical and Pharmaceutical Research” in the journal Nature.
Tuesday, September 20, 2011
Metabolon Secures $13 Million in Series D Financing
New investor Keating Capital, Inc. joins existing investors including Sevin Rosen Funds, Aurora Funds, Harris & Harris Group, Syngenta Ventures, Fletcher Spaght and Fulcrum Financial Partners in the round.
Tuesday, August 30, 2011
Two Studies Provide Insight into Kidney Cancer
Metabolon, Inc. announces the publication of studies in two peer-reviewed journals that support the use of metabolomics in the diagnosis and treatment of kidney cancer.
Tuesday, August 16, 2011
Research into Dietary Leucine
Metabolon, Inc. announces the publication of “Dietary Leucine - An Environmental Modifier of Insulin Resistance Acting on Multiple Levels of Metabolism” in PLoS One.
Tuesday, July 19, 2011
USPTO Grants Two New Patents to Metabolon
Metabolon currently holds 17 US Patents related to its biochemical profiling methods, data analysis solutions and biomarkers for disease and toxicity.
Monday, June 20, 2011
Scientific News
Gut Microbes Signal to the Brain When They're Full
Don't have room for dessert? The bacteria in your gut may be telling you something.
Turning up the Tap on Microbes Leads to Better Protein Patenting
Mining millions of proteins could become faster and easier with a new technique that may also transform the enzyme-catalyst industry, according to University of California, Davis, researchers.
Drug May Prevent Life-Threatening Muscle Loss in Advanced Cancers
New data describes how an experimental drug can stop life-threatening muscle wasting (cachexia) associated with advanced cancers and restore muscle health.
Cancer-Fighting Tomato Component Traced
The metabolic pathway associated with lycopene, the bioactive red pigment found in tomatoes, has been traced by researchers at the University of Illinois.
Circadian Clock Controls Insulin and Blood Sugar in Pancreas
Map of thousands of genes suggests new therapeutic targets for diabetes.
Cellular Stress Process Identified in Cardiovascular Disease
Combining the investigative tools of genetics, transcriptomics, epigenetics and metabolomics, a Duke Medicine research team has identified a new molecular pathway involved in heart attacks and death from heart disease.
Predicting Adverse Drug Reactions with Higher Confidence
A new integrated computational method helps predicting adverse drug reaction—which are often lethal—more reliably than with traditional computing methods.
A New Way to Starve Lung Cancer?
Metabolic alterations in lung cancer may open new avenues for treating the disease.
Evidence of How Incurable Cancer Develops
Researchers in the West Midlands have made a breakthrough in explaining how an incurable type of blood cancer develops from an often symptomless prior blood disorder.
Building a Better Liposome
Computational models suggest new design for nanoparticles used in targeted drug delivery.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos